How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

189 results for

autism and aripiprazole

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Aripiprazole for autism spectrum disorders (ASD). (Abstract)

Aripiprazole for autism spectrum disorders (ASD). Autism spectrum disorders (ASD) include autistic disorder, Asperger's disorder and pervasive developmental disorder - not otherwise specified (PDD-NOS). Antipsychotics have been used as a medication intervention for irritability related to ASD. Aripiprazole, a third-generation, atypical antipsychotic, is a relatively new drug that has a unique mechanism of action different from that of other antipsychotics. This review updates a previous (...) Cochrane review on the safety and efficacy of aripiprazole for individuals with ASD, published in 2011 (Ching 2011).To assess the safety and efficacy of aripiprazole as medication treatment for individuals with ASD.In October 2015, we searched the Cochrane Central Register of Controlled Trials (CENTRAL), Ovid MEDLINE, Embase, the Cumulative Index to Nursing and Allied Health Literature (CINAHL) and seven other databases as well as two trial registers. We searched for records published in 1990 or later

2016 Cochrane

2. Aripiprazole Oral Solution in the Treatment of Children and Adolescents With Autistic Disorder

Additional relevant MeSH terms: Layout table for MeSH terms Disease Autistic Disorder Pathologic Processes Autism Spectrum Disorder Child Development Disorders, Pervasive Neurodevelopmental Disorders Mental Disorders Pharmaceutical Solutions Aripiprazole Antidepressive Agents Psychotropic Drugs Antipsychotic Agents Tranquilizing Agents Central Nervous System Depressants Physiological Effects of Drugs Dopamine Agonists Dopamine Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action (...) Aripiprazole Oral Solution in the Treatment of Children and Adolescents With Autistic Disorder Aripiprazole Oral Solution in the Treatment of Children and Adolescents With Autistic Disorder - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one

2018 Clinical Trials

3. Aripiprazole for Irritability in Asian Children and Adolescents with Autistic Disorder: A 12-Week, Multinational, Multicenter, Prospective Open-Label Study. (Abstract)

Aripiprazole for Irritability in Asian Children and Adolescents with Autistic Disorder: A 12-Week, Multinational, Multicenter, Prospective Open-Label Study. We investigated the effectiveness and tolerability of aripiprazole in the treatment of irritability in Asian children and adolescents (6-17 years) with autistic disorder in a 12-week, multinational, multicenter, open-label study.Sixty-seven subjects (10.0 ± 3.1 years old, 52 boys) were enrolled and treated with flexibly dosed aripiprazole (...) and no serious adverse event related to aripiprazole treatment was noted.Our results suggest that aripiprazole is effective and generally tolerable in the treatment of irritability in Asian children and adolescents with autistic disorder. Further studies with larger sample sizes and longer treatment durations are required.

2018 Journal of Child and Adolescent Psychopharmacology

4. Aripiprazole Mylan - aripiprazole

undesirable effects including EPS related events, somnolence, fatigue and weight gain. Doses higher than 10 mg/day should therefore only be used in exceptional cases and with close clinical monitoring. Younger patients are at increased risk of experiencing adverse events associated with aripiprazole. Therefore, Aripiprazole Mylan is not recommended for use in patients below 13 years of age. Aripiprazole Mylan EMA/CHMP/705827/2014 Page 8/39 Irritability associated with autistic disorder: the safety (...) Aripiprazole Mylan - aripiprazole 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2015. Reproduction is authorised provided the source is acknowledged. 20 November 2014 EMA/CHMP/705827/2014 Committee for Medicinal Products for Human Use (CHMP) Withdrawal Assessment report Aripiprazole Mylan

2015 European Medicines Agency - EPARs

5. Aripiprazole

/day or aripiprazole 15 mg/day for 6 weeks. Outcomes included change from baseline to week 6 in the Positive and Negative Syndrome Scale total score, Barratt Impulsiveness Scale 11-item 2016 17. Head-to-Head Comparison of Aripiprazole and Risperidone in the Treatment of ADHD Symptoms in Children with Autistic Spectrum Disorder and ADHD: A Pilot, Open-Label, Randomized Controlled Study. 27278054 2016 06 25 2016 12 13 2016 12 30 1179-2019 18 4 2016 Aug Paediatric drugs Paediatr Drugs Head-to-Head (...) Comparison of Aripiprazole and Risperidone in the Treatment of ADHD Symptoms in Children with Autistic Spectrum Disorder and ADHD: A Pilot, Open-Label, Randomized Controlled Study. 319-29 (...) and aripiprazole for treating ADHD symptoms in patients with both ASD and ADHD over the course of 24 weeks of treatment. Patients (n = 44) were randomly assigned to start treatment with risperidone (22 patients) or aripiprazole (22 patients). Children were evaluated before starting treatment (T0), and after 12

2018 Trip Latest and Greatest

6. Post-Marketing Surveillance Study of Aripiprazole in Patients With Autism

for additional information Studies a U.S. FDA-regulated Drug Product: No Studies a U.S. FDA-regulated Device Product: No Additional relevant MeSH terms: Layout table for MeSH terms Autistic Disorder Autism Spectrum Disorder Child Development Disorders, Pervasive Neurodevelopmental Disorders Mental Disorders Aripiprazole Antidepressive Agents Psychotropic Drugs Antipsychotic Agents Tranquilizing Agents Central Nervous System Depressants Physiological Effects of Drugs Dopamine Agonists Dopamine Agents (...) Post-Marketing Surveillance Study of Aripiprazole in Patients With Autism Post-Marketing Surveillance Study of Aripiprazole in Patients With Autism - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Post

2017 Clinical Trials

7. Aripiprazole Zentiva

Active Pharmaceutical Ingredient AR Assessment Report ARP aripiprazole ASD autism spectrum disorders ASM Active Substance Manufacturer ASMF Active Substance Master File = Drug Master File AUC area under the curve AUC0-8 area under the curve from time zero to infinity BE Bioequivalence BMI body mass index BP British Pharmacopoeia BPRS brief psychiatric rating scale CEP Certificate of Suitability of the Ph.Eur. CGI clinical global impression CGI-BV clinical global impression bipolar version CGI-S (...) Aripiprazole Zentiva 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact 23 April 2015 EMA/CHMP/232319/2015 Committee for Medicinal Products for Human Use (CHMP) Assessment report Aripiprazole Zentiva International non-proprietary name: aripiprazole Procedure No. EMEA/H/C/003899/0000 Note Assessment report as adopted by the CHMP

2015 European Medicines Agency - EPARs

8. Head-to-Head Comparison of Aripiprazole and Risperidone in the Treatment of ADHD Symptoms in Children with Autistic Spectrum Disorder and ADHD: A Pilot, Open-Label, Randomized Controlled Study. (Abstract)

Head-to-Head Comparison of Aripiprazole and Risperidone in the Treatment of ADHD Symptoms in Children with Autistic Spectrum Disorder and ADHD: A Pilot, Open-Label, Randomized Controlled Study. Autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD) are frequently overlapping neurodevelopmental disorders. Individuals in whom the disorders are comorbid show more severe impairment because of deficits in the processing of social situations, adaptive functioning (...) , and executive control than individuals with either disorder alone.This open-label pilot study aimed to evaluate and compare the efficacy and tolerability of risperidone and aripiprazole for treating ADHD symptoms in patients with both ASD and ADHD over the course of 24 weeks of treatment.Patients (n = 44) were randomly assigned to start treatment with risperidone (22 patients) or aripiprazole (22 patients). Children were evaluated before starting treatment (T0), and after 12 weeks (T1) and 24 weeks (T2

2016 Paediatric Drugs Controlled trial quality: uncertain

9. Aripiprazole in the Treatment of Irritability in Children and Adolescents with Autism Spectrum Disorder in Japan: A Randomized, Double-blind, Placebo-controlled Study. Full Text available with Trip Pro

Aripiprazole in the Treatment of Irritability in Children and Adolescents with Autism Spectrum Disorder in Japan: A Randomized, Double-blind, Placebo-controlled Study. We evaluated the efficacy and safety of aripiprazole in the treatment of irritability in children and adolescents (6-17 years) with autism spectrum disorder (ASD) in a randomized, double-blind, placebo-controlled 8-week study in Japan. Patients received flexibly dosed aripiprazole (1-15 mg/day) or placebo. Ninety-two patients (...) were randomized to placebo (n = 45) or aripiprazole (n = 47). Aripiprazole produced a significant improvement in the mean parent/caregiver-rated Aberrant Behavior Checklist Japanese Version irritability subscale score relative to placebo from week 3 through week 8. Administration of aripiprazole provided significantly greater improvement in the mean clinician-rated Clinical Global Impression-Improvement scores than placebo from week 2 through week 8. All patients randomized to aripiprazole

2016 Child psychiatry and human development Controlled trial quality: uncertain

10. Aripiprazole for treating irritability in children & adolescents with autism: A systematic review. Full Text available with Trip Pro

Aripiprazole for treating irritability in children & adolescents with autism: A systematic review. No clear therapeutic benefits of antipsychotics have been reported for the treatment of behavioural symptoms in autism. This systematic review provides an assessment of evidence for treating irritability in autism by aripiprazole.The databases of MEDLINE/PubMed and Google Scholar were searched for relevant articles about the effect of aripiprazole in children with autism. The articles were (...) searched according to the inclusion and exclusion criteria specifed for this review. All the double-blind, controlled, randomized, clinical trials examining the efficacy of aripiprazole for treating children and adolescents with autism were included.From the 93 titles identified, 26 were irrelevant and 58 were evaluated for more details. Only five articles met the inclusive criteria. The evidence from precise randomized double blind clinical trials of aripiprazole for the treatment of autism

2015 The Indian journal of medical research

11. Interventions Targeting Sensory Challenges in Children with Autism Spectrum Disorder - An Update

: 21220213.X-1 D-55 642. Ghanizadeh A. Can tactile sensory processing differentiate between children with autistic disorder and asperger's disorder? Innov Clin Neurosci. 2011 May;8(5):25-30. PMID: 21686145.X-1 643. Ghanizadeh A. A novel hypothesized clinical implication of zonisamide for autism...Ann Neurol. 2010 Feb;67(2):239- 49. Annals of Neurology. 2011;69(2):426- 1p. doi: 10.1002/ana.22153. PMID: 104841194. Language: English. Entry Date: 20110527. Revision Date: 20150711. Publication Type: Journal (...) : 104685451. Language: English. Entry Date: 20110930. Revision Date: 20150711. Publication Type: Journal Article.X-1, X-2 668. Hellings JA, Boehm D, Yeh HW, et al. Long-term aripiprazole in youth with developmental disabilities including autism. Journal of Mental Health Research in Intellectual Disabilities. 2011 2015-12- 09;4(1):40-52. doi: http://dx.doi.org/10.1080/19315864.2010.54 2274. PMID: 872590596; 2011-05041- 003.X-1, X-3 669. Hepburn SL, Moody EJ. Diagnosing Autism in Individuals with Known

2017 Effective Health Care Program (AHRQ)

12. Aripiprazole Toxicity With a Biphasic Course of Somnolence. (Abstract)

Aripiprazole Toxicity With a Biphasic Course of Somnolence. Aripiprazole is an atypical antipsychotic with partial agonism at dopamine and serotonin receptors. In pediatrics, it is approved to treat irritability associated with autistic disorder along with other neuropsychological conditions. Compared with other atypical antipsychotics, it has a favorable side effect profile, but overdose experience is limited.A 3-year-old drug-naive patient accidentally ingested 200 mg of aripiprazole (...) . This ingestion resulted in immediate lethargy with brief improvement 16 hours after ingestion and subsequent decline 2 hours later. Patient returned to baseline 72 hours after ingestion.Unlike previous case reports, this patient displayed a biphasic course of somnolence. Previous reports have described delayed onset and prolonged sedation in response to an aripiprazole overdose. Current recommendations regarding monitoring after ingestion do not account for possible worsening of symptoms after improvement.It

2019 Pediatric Emergency Care

13. Assessment, diagnosis and interventions for autism spectrum disorders

. The inclusion of adults is in response to the increasing understanding that autism spectrum disorder (ASD) is a lifelong condition in which the core features of ASD persist whilst manifesting differently according to different age stages. Depending on the severity of autistic difficulties, ASD may not be evident as a presentation throughout preschool, primary, or secondary school years or in adulthood. It may not be recognised because of associated coexisting conditions. Variable environmental factors (...) on cognition. A study conducted in a gender clinic in London reported that among the 92 participants the prevalence of autistic traits, based on assessment with the Autism Spectrum Quotient (AQ) was 5.5% (3 male to female and 2 female to male transsexuals) compared to reports of clinical diagnoses of 0.5–2.0% in the general population. 49 Further indicators of possible ASD in adults are listed in Annex 2. Healthcare professionals should be aware of indicators for ASD in adults presenting with other

2016 SIGN

14. Behavioral Mechanisms That Depend on Dopamine and Serotonin in Caenorhabditis elegans Interact With the Antipsychotics Risperidone and Aripiprazole Full Text available with Trip Pro

genes. Risperidone and aripiprazole are a class of drugs known as atypical antipsychotics commonly used to treat schizophrenia, bipolar disorder, and irritability associated with autism. Risperidone is an antagonist of the dopamine D2 and serotonin 5-HT2A receptors. Aripiprazole functions as a partial agonist of the dopamine D2 receptor and as a partial agonist and antagonist of 5-HT1A and 5-HT2A serotonin receptors, respectively. Our results show that risperidone and aripiprazole alter the touch (...) Behavioral Mechanisms That Depend on Dopamine and Serotonin in Caenorhabditis elegans Interact With the Antipsychotics Risperidone and Aripiprazole The neurotransmitters dopamine and serotonin participate in specific behavioral neuromuscular mechanisms in the nematode Caenorhabditis elegans. Dopamine is involved in the gentle touch response and serotonin in the pharyngeal pumping rate. In its genome, the worm presents genes encoding dopamine and serotonin receptors orthologous to those of human

2018 Journal of Experimental Neuroscience

15. Aripiprazole Oral Solution in the Treatment of Children and Adolescents With Tourette's Syndrome

Aripiprazole Oral Solution in the Treatment of Children and Adolescents With Tourette's Syndrome Aripiprazole Oral Solution in the Treatment of Children and Adolescents With Tourette's Syndrome - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one (...) or more studies before adding more. Aripiprazole Oral Solution in the Treatment of Children and Adolescents With Tourette's Syndrome The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03487783 Recruitment Status : Recruiting

2018 Clinical Trials

16. A randomized controlled trial investigating the safety and efficacy of aripiprazole in the long-term maintenance treatment of pediatric patients with irritability associated with autistic disorder. (Abstract)

A randomized controlled trial investigating the safety and efficacy of aripiprazole in the long-term maintenance treatment of pediatric patients with irritability associated with autistic disorder. To evaluate the efficacy and safety of aripiprazole versus placebo in preventing relapse of irritability symptoms associated with autistic disorder in pediatric patients.This multicenter, double-blind, randomized, placebo-controlled, relapse-prevention trial enrolled patients (6-17 years) who met (...) the current Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DMS-IV-TR) criteria for autistic disorder and who also had serious behavioral problems (ie, tantrums, aggression, self-injurious behavior, or a combination of these behavioral problems) between March 2011 and June 2012. In phase 1, single-blind aripiprazole was flexibly dosed (2-15 mg/d) for 13-26 weeks. Patients with a stable response (≥ 25% decrease in Aberrant Behavior Checklist-irritability subscale score

2014 Journal of Clinical Psychiatry Controlled trial quality: predicted high

17. Aripiprazole Decreases Irritability in 12 out of 14 Youth with Autism Spectrum Disorders Full Text available with Trip Pro

Aripiprazole Decreases Irritability in 12 out of 14 Youth with Autism Spectrum Disorders 24828130 2015 10 22 2018 11 13 1557-8992 24 6 2014 Aug Journal of child and adolescent psychopharmacology J Child Adolesc Psychopharmacol Aripiprazole decreases irritability in 12 out of 14 youth with autism spectrum disorders. 357-9 10.1089/cap.2013.0143 Maloney Ann A Department of Psychiatry, UMASS Medical School , Worcester, Massachusetts. Mick Eric O EO Frazier Jean J eng P30HD004147 HD NICHD NIH HHS (...) United States Clinical Trial Letter Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't 2014 05 14 United States J Child Adolesc Psychopharmacol 9105358 1044-5463 0 Antipsychotic Agents 0 Piperazines 0 Quinolones 82VFR53I78 Aripiprazole IM Adolescent Antipsychotic Agents therapeutic use Aripiprazole Child Child Development Disorders, Pervasive drug therapy physiopathology Female Humans Irritable Mood drug effects Male Piperazines therapeutic use Quinolones therapeutic use Treatment

2014 Journal of Child and Adolescent Psychopharmacology

18. A randomized controlled trial investigating the safety and efficacy of aripiprazole in the long-term maintenance treatment of pediatric patients with irritability associated with autistic disorder. (Abstract)

A randomized controlled trial investigating the safety and efficacy of aripiprazole in the long-term maintenance treatment of pediatric patients with irritability associated with autistic disorder. To evaluate the efficacy and safety of aripiprazole versus placebo in preventing relapse of irritability symptoms associated with autistic disorder in pediatric patients.This multicenter, double-blind, randomized, placebo-controlled, relapse-prevention trial enrolled patients (6-17 years) who met (...) the current Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DMS-IV-TR) criteria for autistic disorder and who also had serious behavioral problems (ie, tantrums, aggression, self-injurious behavior, or a combination of these behavioral problems) between March 2011 and June 2012. In phase 1, single-blind aripiprazole was flexibly dosed (2-15 mg/d) for 13-26 weeks. Patients with a stable response (≥ 25% decrease in Aberrant Behavior Checklist-irritability subscale score

2014 Journal of Clinical Psychiatry Controlled trial quality: predicted high

19. The effectiveness of aripiprazole in the management of problem behaviour in people with intellectual disabilities, developmental disabilities and/or autistic spectrum disorder - A systematic review. (Abstract)

The effectiveness of aripiprazole in the management of problem behaviour in people with intellectual disabilities, developmental disabilities and/or autistic spectrum disorder - A systematic review. The management of problem behaviours (PB) in individuals with intellectual disabilities (ID), developmental disabilities (DD) and/or autistic spectrum disorders (ASD) can be challenging. Antipsychotic medications are commonly prescribed where other strategies have failed. A systematic review (SR (...) ) was conducted to establish the research evidence for the efficacy of aripiprazole in the management of PB in adults and children with ID, DD and/or ASD. Although included studies supported the efficacy of aripiprazole for this indication, the overall quality of studies was poor. Of the 20 studies included in this systematic review there were only two randomised controlled trials (RCTs) on children with ASD and/or ID/DD, both of which were conducted by the pharmaceutical company that manufactures

2014 Research in developmental disabilities

20. A Head-to-Head Comparison of Aripiprazole and Risperidone for Safety and Treating Autistic Disorders, a Randomized Double Blind Clinical Trial. Full Text available with Trip Pro

A Head-to-Head Comparison of Aripiprazole and Risperidone for Safety and Treating Autistic Disorders, a Randomized Double Blind Clinical Trial. Aripiprazole and risperidone are the only FDA approved medications for treating irritability in autistic disorder, however there are no head-to-head data comparing these agents. This is the first prospective randomized clinical trial comparing the safety and efficacy of these two medications in patients with autism spectrum disorders. Fifty nine (...) children and adolescents with autism spectrum disorders were randomized to receive either aripiprazole or risperidone for 2 months. The primary outcome measure was change in Aberrant Behavior Checklist (ABC) scores. Adverse events were assessed. Aripiprazole as well as risperidone lowered ABC scores during 2 months. The rates of adverse effects were not significantly different between the two groups. The safety and efficacy of aripiprazole (mean dose 5.5 mg/day) and risperidone (mean dose 1.12 mg/day

2014 Child psychiatry and human development Controlled trial quality: uncertain

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>